Welcome to our Q3 presentation. We had a challenging quarter, but let me start by zooming out a bit. Let me briefly take you through Sieradz's long-term strategy and our progress for Q3. Sieradz is active in the field of radiation therapy, and approximately half of all cancer patients receive radiation therapy as part of their treatment; we continue to invest in our world-leading products. Sieradz is in a very strong position with our entire portfolio interfacing all major LINACs, Protons, and CT vendors. This is our most extensive interoperability portfolio ever. Sieradz already today has a global reach, but we are constantly looking into market expansions. And we do this step by step. Growing our global presence is strengthening Sieradz's resilience. And in the third quarter, we continue to see the result of our enhanced focus on the less mature Southeast Asian markets. We are ramping up our investment in Latin America, where we had a successful training in connection with Astro, the med tech show, for the Latin American distributors. And why is that important? Sieradz sees an untapped potential in many markets, which we want to capture at the right time. This quarter, we had several US retrofit wins on Varian LINACs, and it's important to us for two reasons. Number one, addressing the LINACs that do not yet have Surface Guided Radiation Therapy or SGRT. And number two: strengthening our position in the US market. And finally, Sieradz has good financial stability. And for this quarter we have displayed solid profitability despite the headwinds in the EMEA region, while we are simultaneously investing for growth. So let's take a look at our Q3 numbers. We ended the third quarter with an order intake of 100 million MSEK, a decline of 40%, or 38% in constant currencies from an unusually strong Q3 '23. And clearly, this is below our expectations. The weak performance in EMEA could not be compensated by the strong performance in APAC, nor by the performance in the Americas during the quarter.
While we had eight quarters of very strong revenue growth, in the third quarter, we are down 10% from the same quarter last year, or 7% in constant currencies with revenue of 100 million CC. This is mainly driven by lower order intake and the timing of our backlog. However, it should be noted that this is our fifth consecutive quarter with revenue exceeding 100 million SEK. And as I just mentioned, we continue to build market resilience, preparing our sales readiness for selected emerging markets. The sales cycles in our business are long, so we must prepare ourselves well ahead of time. And despite the headwinds, we have a solid EBIT margin of 17%. The order backlog of 735 million SEK is on the same level as in the third quarter of last year. So let's look into the regional performance in the quarter.
As I already mentioned, EMEA had another challenging quarter.
Order intake decreased 77% to 23 million SEK. It is a very tough comparison. And you might recall that we received three unusually large orders in Q3 last year. The main factor is the macroeconomic slowdown in Germany and continued slower decision-making. And this is indeed true for service contract extensions in EMEA. There have been fewer large tenders for the first three quarters of the year. Middle East, an emerging market for us, is moving slower and decision-making is taking longer than initially expected, impacted by the geopolitical situation. Revenue decreased 41% to 32 million SEK, affected by a lower order intake and a slower backlog conversion. Without a doubt, however, there is untapped potential in advanced markets. There are also regional highlights with good performance in Central Eastern Europe for this quarter. But as I already said, this is below our expectation. So what are we doing? We have increased our market activity with targeted sales campaigns, attending local trade shows, intensifying our marketing efforts, and expanding our activities in the retrofit markets. In addition, we are proactively reaching out to existing customers to ensure that we are on top of their clinical training needs, and staying close to our customers is beneficial to us as they are important references for new business opportunities. For the Americas, we had good progress in the quarter. Order intake increased by 10% to 28 million SEK, while revenue declined by 10% to 23 million SEK. Our long-term focus on strengthening our position in the US market by increasing our focus on the Varian install base is starting to pay off. We had some good wins on Varian LINACs this quarter, and Latin America is on the rise. Latin America is a market where the number of LINACs per million is only two, versus the W.H.O. recommendation of four LINACs per million inhabitants. recommendation of four LINACs per million inhabitants. And putting this into perspective, the number for the US is twelve. An indication of this potential is that after the closing of the quarter, we received a 10 million SEK order in Mexico. And lastly, the APAC region continued to perform well in the quarter.
Order intake was up 11% to 48 million SEK, and revenue increased 43% to $45 million. There is large unmet demand in Southeast Asia. And we see, in fact, more and more tenders, including SGRT from the start. Australia continues to invest in SGRT, and our position in this advanced market is very strong. Japan is also contributing to the strong performance in the quarter, and last year, we secured our first service contracts in China and added more contracts this quarter. And with that, over to you, Linda, for a closer look at the financials.